<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229955</url>
  </required_header>
  <id_info>
    <org_study_id>HL_TSPR_302</org_study_id>
    <nct_id>NCT02229955</nct_id>
  </id_info>
  <brief_title>Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease</brief_title>
  <acronym>HL_TSPR_302</acronym>
  <official_title>A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic
      solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12
      weeks after treatment, each treatment group comparisons for evaluation of efficacy and safety
      in Moderate to Severe Dry Eye Disease.

      - Corneal staining test, Ocular surface disease index (OSDI), Tear break up time (TBUT),
      Non-anesthetic Schirmer test
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal staining test</measure>
    <time_frame>4, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index (OSDI)</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear break up time (TBUT)</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-anesthetic Schirmer test</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>T-sporin eye drop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis eye drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine ophthalmic solution</intervention_name>
    <description>1 drop twice/day for 12 weeks to both eyes</description>
    <arm_group_label>T-sporin eye drop</arm_group_label>
    <arm_group_label>Restasis eye drop</arm_group_label>
    <other_name>Restasis Eye Drops</other_name>
    <other_name>Tisporin Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [Patients with moderate-to-severe ocular dry eye]

          1. The One eye of corneal fluorescein staining score of 2 or higher (Oxford grading)

          2. Non-anesthetic Schirmer test value ≤ 10mm/5min patients at least one eye score
             (Non-anesthetic Schirmer test value = 0/5min, nasal stimulation in the same eye,
             Schirmer test value ≥ 3mm/5min)

          3. Tear break-up time is 10 seconds or less

          4. Screening both eyes, the corrected visual acuity is 0.2 or more

          5. Despite conventional treatment, the symptoms of dry eye signs (Artificial tear eye
             drops, sympathetic nervous system stimulant agent, parasympathetic nerve stimulant,
             etc.)

        Exclusion Criteria:

          1. Screening visits in the previous 3 months (12 weeks) who participated in the clinical
             trials of cyclosporine eye drops, or if you used a cyclosporin ophthalmic solutions.

          2. The patients with systemic or ocular disorders affected the test results (ocular
             surgery, trauma, or disease)

               1. Abnormal eyelid function : Disoders of the eyelids or eyelashes

               2. Ocular allergies or currently under the treatment of allergic diseases of the eye
                  (topical ocular mast cell stabilizer, antihistamine use, etc.)

               3. Cicatricial keratoconjunctivitis caused by herpetic keratopathy, conjunctival
                  scarring (alkali damage, Steven-Johnson syndrome, cicatricial pemphigoid),
                  pterygium, pinguecula, lack of congenital lacrimal, neurogenic keratitis,
                  keratoconus, corneal transplantation

          3. current or recent patients used dry eye syndrome medications (topical or systemic)
             that may affect the status

          4. The use in clinical trials of drug hypersensitivity reactions in patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The catholic university of Korea seoul st. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-Ku</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

